Pharsight

Tymlos generic

Tymlos is an osteoporosis drug owned by Radius Health Inc. It contains the active ingredient abaloparatide. Tymlos was first authorized for market use on April 28, 2017.

When will Tymlos generic be available?

The last patent for Tymlos is expected to expire on January 10, 2040, allowing the potential release of Tymlos generics.

Tymlos uses

Tymlos is used to increase bone density in men with osteoporosis at high risk for fracture, and serves as a treatment option for postmenopausal women with osteoporosis at high risk for fracture. It can also be used for detecting neutralizing antibodies.

Tymlos patent expiration

Tymlos has a total of 7 drug patents, none of which have expired. The last Tymlos patent is set to expire on January 10, 2040. The patents cover methods of drug delivery, composition, and uses. Tymlos generics will likely emerge after this date. Below are the details of the patent:

EPO Oppostions filed on Tymlos

Tymlos dosage

Want to ask something?